Bone

Hip Innovation Technology Announces Positive Clinical Study Data of its Novel Reverse Hip Replacement System for the Treatment of Total Hip Arthroplasty

Retrieved on: 
Wednesday, June 28, 2023
Osteoarthritis, Bone, Obesity, University, Arthralgia, Associate professor, Roentgen, Ageing, Quality of life, BOCA, HIT, Trial of the century, Reverse, RSA, Agency for Healthcare Research and Quality, Concordia, MD, Patient, Agency, Rheumatoid arthritis, Entrepreneurship, Hospital, Roentgen stereophotogrammetry, Safety, SD, Total, Female, Medical device, Dentistry, Avascular necrosis

BOCA RATON, Fla., June 28, 2023 /PRNewswire/ --  Hip Innovation Technology, LLC (HIT), a medical device company developing innovative orthopedic device solutions to advance the quality of life and quality of care for patients, today announces the publication of one of its clinical studies. The article entitled, "Radiostereometric analysis and clinical outcomes of a novel reverse total hip system at two years," was published in the most recent issue of Bone & Joint Open journal.

Key Points: 
  • The article entitled, "Radiostereometric analysis and clinical outcomes of a novel reverse total hip system at two years," was published in the most recent issue of Bone & Joint Open journal.
  • This study enrolled 22 patients (11 male/11 female; median age 70.6 years) and evaluated implant fixation using radiostereometric analysis (RSA).
  • Hip replacement surgery, or total hip arthroplasty, is one of the most common joint replacement procedures done in the United States.
  • Total hip replacements are one of the most effective ways to reduce joint pain and improve functioning for patients with advanced hip problems.

Gleamer Raises €27 Million in Series B Funding Round to Expand its AI Solutions Portfolio and Speed up International Expansion

Retrieved on: 
Wednesday, June 28, 2023
Health, Medical Devices, Technology, Software, Radiology, Artificial Intelligence, Biotechnology, DNA, CT, Pulmonary pathology, Catalog, Bone, Radiological Society of North America, Certification, MDR, Publication, Patient, Investment, MSK, Diagnosis, Estonia, RSNA, FDA, Mammography, Medical device

Today, Gleamer, the leading European manufacturer in AI-powered solutions for medical imaging, announced a Series B financing of €27 million.

Key Points: 
  • Today, Gleamer, the leading European manufacturer in AI-powered solutions for medical imaging, announced a Series B financing of €27 million.
  • This new investment will enable Gleamer to expand its portfolio of solutions, strengthen its European and American teams, and accelerate its international development plans.
  • Total funds raised to date amount to €36 million (which includes a Series A funding round of €7.5 million in 2020 and seed funding of €1.5 million in 2018).
  • Tomorrow, by extending its portfolio of solutions to CT scans and mammography, Gleamer will cover 70% of radiologists' daily needs.

The Inner Circle Acknowledges, Carrie Watson, DO, FACOS as a Distinguished Healthcare Provider for her contributions to the Trauma Surgery Field

Retrieved on: 
Thursday, June 22, 2023
Internal bleeding, Communication, UF Health Shands Hospital, Surgeon, University, Education, Osteopathy, Advanced trauma life support, Philadelphia College of Osteopathic Medicine, OH, Shock, Hope, Trauma, Medicine, Level 2, Bone, Inner circle, DO, University of Oklahoma College of Medicine, Injury, ROCK, Honors colleges and programs, Inguinal hernia surgery, Patient, Physician, Rock Hill, South Carolina, General surgery, Hospital, Nursing care plan, ICU, Burns, American College, Piedmont, Environment, Family, Nursing, Dentistry, Psychology

ROCK HILL, S.C., June 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Carrie Watson, DO, FACOS, is acknowledged as a Distinguished Healthcare Provider for her contributions to the Trauma Surgery Field.

Key Points: 
  • ROCK HILL, S.C., June 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Carrie Watson, DO, FACOS, is acknowledged as a Distinguished Healthcare Provider for her contributions to the Trauma Surgery Field.
  • She capped her scholarship at the UF Health Shand's Hospital in Gainesville completing a surgical critical care fellowship.
  • According to Dr. Watson, trauma surgery is a specialty that utilizes both operative and non-operative management to treat traumatic injuries, typically in an acute setting.
  • She notes that trauma surgeons generally complete residency training in general surgery and often fellowship training in trauma or surgical critical care.

Rani Therapeutics’ Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Retrieved on: 
Wednesday, June 21, 2023
ENDO, Abstract, Bone, Teriparatide, Osteoporosis, Drug, Volunteering, Tech, DSM-IV codes, PTH, Patient, SAN, Fertility, Endocrine Society, Rare, News, Parathyroid hormone, Pharmaceutical industry

The Endocrine Society committee recognized Rani for its exceptional scientific work on RT-102, the company’s oral robotic RaniPill® delivering teriparatide, or parathyroid hormone (PTH) (1-34), which is being developed as an oral osteoanabolic therapy for osteoporosis.

Key Points: 
  • The Endocrine Society committee recognized Rani for its exceptional scientific work on RT-102, the company’s oral robotic RaniPill® delivering teriparatide, or parathyroid hormone (PTH) (1-34), which is being developed as an oral osteoanabolic therapy for osteoporosis.
  • In addition, results of the RT-102 study and its clinical implications were presented and discussed by Dr. Arvinder Dhalla, Vice President of Clinical Development in a Tech news conference hosted by The Endocrine Society.
  • Of the 2,500 submitted abstracts, The Endocrine Society selected 15 abstracts to be presented during the news conference and 18 were named Presidential Poster Competition winners.
  • “We are honored and humbled by the overwhelming endorsement of our work by our scientific peers this week at ENDO 2023 which culminated in the Presidential Poster Competition award.

MARS's Spectral Imaging Photon Counting Point-of-Care CT Scanner System

Retrieved on: 
Thursday, June 15, 2023
CERN, Radiology, Higgs boson, Bone density, Bone, Research, European Laboratory for Non-Linear Spectroscopy, Organization, Hospital for Special Surgery, MD, HSS, Physics, Diagnosis, Hospital, Health, Particle physics, Medical imaging, Nursing

Through the HSS Innovation Institute, HSS and MARS will collaborate to advance musculoskeletal imaging and diagnosis, including evaluation of specific aspects of the MARS 5x120 Extremity Scanner and potential co-development of new scanning technologies and systems.

Key Points: 
  • Through the HSS Innovation Institute, HSS and MARS will collaborate to advance musculoskeletal imaging and diagnosis, including evaluation of specific aspects of the MARS 5x120 Extremity Scanner and potential co-development of new scanning technologies and systems.
  • The MARS 5x120 Extremity scanner is based on detector technology that was initially developed as part of ongoing particle physics research at the European Laboratory for Particle Physics (CERN), where the Higgs Boson was discovered.
  • The MARS 5x120 Extremity scanner is designed as a "point-of-care" system, intended for use in clinical office and ambulatory settings, addressing clinical needs such as pre- and post-surgical planning, assessment of fracture healing, and identification of implant complications.
  • "We're pleased that a world-class clinical organization like HSS sees the potential for the MARS CT scanning technology," says MARS CEO Mark Figgitt.

QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®

Retrieved on: 
Wednesday, June 14, 2023
Tissue, Partnership, Radiation, Bone, University, Moses Austin, Cancer, OTCQB, Patient, Physician, QSAM, Nuclear, FDA, NETL, Void coefficient, Disease, University of Texas at Austin, Medical imaging, Uranium mining

QSAM is actively enrolling patients with metastatic bone cancer in a Phase I clinical trial across four clinical research centers in the United States.

Key Points: 
  • QSAM is actively enrolling patients with metastatic bone cancer in a Phase I clinical trial across four clinical research centers in the United States.
  • “We have established a robust vetting and testing process to evaluate nuclear reactors to include in our supply chain.
  • NETL houses a 1.1-MW nuclear research reactor that is the newest research reactor in the US.
  • The addition of qualified nuclear reactors is expected to support QSAM’s clinical research and future commercial supply of Sm-153 if approved by the FDA.

MIB Agents' Community of Families Has Awarded Over $1.5M in Grants to Research Pediatric Bone Cancer

Retrieved on: 
Wednesday, June 14, 2023
Survivor, Partnership, Bone, Parent, Osteosarcoma, Cancer, Human, Research, Doctor of Philosophy, OutSmart, Estate (law), Noya Fields Family Funds, Patient, MD, Child, Terror, Memory, Conference, Caregiver, Disease, Pharmaceutical industry, Vaccine, Nursing, Harbor

BARNARD, Vt., June 14, 2023 /PRNewswire/ -- MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, caregivers, doctors, and researchers, announced today that since its inception in 2016, it has awarded over $1.5 million to scientists across the country through its OutSmarting Osteosarcoma grant program. The OutSmarting Osteosarcoma grants are supported by MIB Agents Family Funds, osteosarcoma patients and families who raise funds in honor of an OsteoWarrior, a patient currently battling osteosarcoma or an OsteoAngel, a loved one who has passed.

Key Points: 
  • As part of MIB Agents' FACTOR Conference in Atlanta, Georgia, this June, the nonprofit will award $600,000 in grants to 7 scientists dedicated to moving osteosarcoma cancer research forward, marking the most money raised to date by MIB Agents' Family Funds.
  • Osteosarcoma is an aggressive, malignant, primary bone cancer affecting 800-900 people in the U.S. each year and is the most common bone cancer affecting children and young adults.
  • The OutSmarting Osteosarcoma grant represents a partnership between the scientific and patient community with patients and their families funding much-needed research.
  • To learn more about MIB Agents, the OutSmarting Osteosarcoma grant program or to make a donation toward pediatric osteosarcoma research, please click here.

Bioretec Ltd invests in a CNC machining center to increase the RemeOs™ production capacity

Retrieved on: 
Tuesday, June 13, 2023
Health care, Bone, Trauma, Patient, CNC, Activa, Medical device

TAMPERE, Finland, June 13, 2023 /PRNewswire/ -- Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has acquired a new CNC machining center to increase the production capacity of RemeOs™ products at its factory in Tampere, Finland.

Key Points: 
  • TAMPERE, Finland, June 13, 2023 /PRNewswire/ -- Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has acquired a new CNC machining center to increase the production capacity of RemeOs™ products at its factory in Tampere, Finland.
  • "The new CNC machining center will significantly increase our production capacity of RemeOs™ screws for the U.S. market.
  • The addition of our own machining center for RemeOs™ products will also enhance the production of our Activa implants," comments Bioretec CEO Timo Lehtonen.
  • Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of bioresorbable orthopedic implants.

Bioretec Ltd invests in a CNC machining center to increase the RemeOs™ production capacity

Retrieved on: 
Tuesday, June 13, 2023
Health care, Bone, Trauma, Patient, CNC, Activa, Medical device

TAMPERE, Finland, June 13, 2023 /PRNewswire/ -- Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has acquired a new CNC machining center to increase the production capacity of RemeOs™ products at its factory in Tampere, Finland.

Key Points: 
  • TAMPERE, Finland, June 13, 2023 /PRNewswire/ -- Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has acquired a new CNC machining center to increase the production capacity of RemeOs™ products at its factory in Tampere, Finland.
  • "The new CNC machining center will significantly increase our production capacity of RemeOs™ screws for the U.S. market.
  • The addition of our own machining center for RemeOs™ products will also enhance the production of our Activa implants," comments Bioretec CEO Timo Lehtonen.
  • Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of bioresorbable orthopedic implants.

Invibio, Part of Victrex plc, Announces New Collaboration With Paragon Medical to Support Scale Up of PEEK Based Trauma Devices

Retrieved on: 
Friday, June 9, 2023
Engineering, Health, Chemicals, Plastics, Medical Devices, Manufacturing, Pharmaceutical, Biotechnology, Paragon, Intellectual property, Obesity, Surgeon, Diabetes, Osteoporosis, Nonunion, Nail, Bone, Multimedia, Risk, Titanium, Patient, Ultra, PEEK, Trauma, Fatigue, Ceramic, Medical device, Nursing, Victrex

The manufacturing arrangement with Paragon Medical will support the scale up of high quality PEEK-OPTIMA™ ultra-reinforced composite fracture fixation devices, at a time when Invibio is seeing demand exceeding initial expectations.

Key Points: 
  • The manufacturing arrangement with Paragon Medical will support the scale up of high quality PEEK-OPTIMA™ ultra-reinforced composite fracture fixation devices, at a time when Invibio is seeing demand exceeding initial expectations.
  • The announcement coincides with Paragon Medical’s recent expansion of dedicated space for this collaboration in their manufacturing facility in Changzhou, China.
  • The Paragon Medical collaboration can provide Invibio customers with additional world class medical composite manufacturing facilities to help serve growing customer demand for these products.
  • Paragon Medical will help us support manufacturing scale up, and they bring an excellent reputation as one of the world’s premier medical contract manufacturers.